A Randomized PhaseII/III Study of Concurrent Chemoradiotherapy with Low Dose Cisplatin plus 5-FU versus Concurrent Chemoraiotherapy with Standard Dose Cisplatin plus 5-FU for Locally Advanced Unresetable Esophageal Cancer in the Thorax.(JCOG0303)
Phase 2
- Conditions
- ocally advanced unresectable esophageal cancer in the thorax
- Registration Number
- JPRN-UMIN000000861
- Lead Sponsor
- Japan Clinical Oncology Group(JCOG)
- Brief Summary
See the datails via "URL releasing results" above. Also the details can be seen in the JCOG website: http://www.jcog.jp/en/trials/index.html
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 364
Inclusion Criteria
Not provided
Exclusion Criteria
1)Simultaneous or metachronous (within 5 years) double cancers 2)Pregnancy or lactation 3)Serious psychiatric illness 4)Steroid treatment 5)HBs antigen positive 6)Uncontrollable diabetes 7)Myocaedial infarcion within 3 months 8)Serious comorbidity 9)Active bacterial or fungous infection
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method overall survival
- Secondary Outcome Measures
Name Time Method complete response rate, treatment completion rate, treatment completion rate by PS, adverse events